Overview

A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Phase:
PHASE3
Details
Lead Sponsor:
Renibus Therapeutics, Inc.
Treatments:
veverimer